Emergent BioSolutions Inc.

Form 4

March 12, 2014

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

SECURITIES

OMB Number:

3235-0287

Expires:

January 31, 2005

0.5

Estimated average burden hours per

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF

response...

OMB APPROVAL

Check this box if no longer subject to Section 16. Form 4 or

Form 5 obligations may continue. See Instruction

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

1(b).

(Print or Type Responses)

1. Name and Address of Reporting Person * Havey Adam			2. Issuer Name and Ticker or Trading Symbol Emergent BioSolutions Inc. [EBS]	5. Relationship of Reporting Person(s) to Issuer		
(Last)	(First)	(Middle)	3. Date of Earliest Transaction	(Check all applicable)		
			(Month/Day/Year)	Director 10% Owner		
2273 RESEARCH BLVD., SUITE 400		, SUITE	03/11/2014	X Officer (give title Other (specify below)		
	(Street)		4. If Amendment, Date Original	6. Individual or Joint/Group Filing(Check		
ROCKVILLE,	MD 20853		Filed(Month/Day/Year)	Applicable Line) _X_ Form filed by One Reporting Person Form filed by More than One Reporting Person		

(City)	(State)	(Zip) Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned								
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. 4. Securities Acquired Transaction(A) or Disposed of (D) Code (Instr. 3, 4 and 5) (Instr. 8) (A) or			5. Amount of Securities Ownership Form: Direct Owned (D) or Following Indirect (I) Reported (Instr. 4) Transaction(s)	7. Nature of Indirect Beneficial Ownership (Instr. 4)			
Common Stock (1)	03/11/2014		Code V F	Amount 1,336	(D)	Price \$ 28.09	(Instr. 3 and 4) 28,695	D		
Common Stock (1)	03/11/2014		A	14,060	A	\$0	42,755 <u>(2)</u>	D		
Common Stock	03/11/2014		S	5,835	D	\$ 26.96	36,920	D		
Common Stock	03/11/2014		M	4,887	A	\$ 15.83	41,807	D		
Common Stock	03/11/2014		M	6,933	A	\$ 15.91	48,800	D		

Edgar Filing: Emergent BioSolutions Inc. - Form 4

Common 11,820 D \$ 36,920 03/11/2014 S D Stock

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of SEC 1474 information contained in this form are not (9-02)required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)	orDerivative Securities Acquired (Disposed o	*		ate	7. Title and Amount Underlying Securitie (Instr. 3 and 4)	
				Code V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amou or Numb of Sha
Employee Stock Option (right to buy)	\$ 28.09	03/11/2014		A	28,119		(3)	03/10/2021	Common Stock	28,11
Employee Stock Option (right to buy)	\$ 15.91	03/11/2014		M		6,933	<u>(4)</u>	03/08/2014	Common Stock	6,93
Employee Stock Option (right to buy)	\$ 15.83	03/11/2014		M		4,887	<u>(5)</u>	03/12/2019	Common Stock	4,88

Reporting Owners

Relationships Reporting Owner Name / Address Director 10% Owner Officer Other

Havey Adam

2273 RESEARCH BLVD.

SUITE 400

ROCKVILLE, MD 20853

EVP, Biodefense Divison

2 Reporting Owners

Signatures

/s/Eric Burt, attorney-in-fact

03/12/2014

**Signature of Reporting
Person

Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Consists of restricted stock units granted under the Amended and Restated Emergent BioSolutions Inc. 2006 Stock Incentive Plan.
 - These restricted stock units vest in three equal annual installments beginning on the first anniversary of the date of grant, assuming
- (2) continued service with the company. Each restricted stock unit represents the right of the Reporting Person to receive one share of common stock of Emergent BioSolutions Inc., subject to adjustment as provided in the grant agreement.
- (3) Vests in three equal installments on March 10, 2015, March 10, 2016 and March 10, 2017.
- (4) The option is fully vested.
- (5) The option will vest with respect to the remaining 4,887 shares on March 12, 2015.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

Signatures 3